表紙
市場調查報告書

細胞毒性T淋巴球蛋白質4 (CTLA-4,CD152) :開發中產品分析

Cytotoxic T Lymphocyte Protein 4 - Pipeline Review, H2 2019

出版商 Global Markets Direct 商品編碼 363120
出版日期 內容資訊 英文 237 Pages
訂單完成後即時交付
價格
Back to Top
細胞毒性T淋巴球蛋白質4 (CTLA-4,CD152) :開發中產品分析 Cytotoxic T Lymphocyte Protein 4 - Pipeline Review, H2 2019
出版日期: 2019年11月25日內容資訊: 英文 237 Pages
簡介

本報告提供細胞毒性T淋巴球蛋白質4 (CTLA-4,CD152)的開發情形調查分析,提供您開發中產品的概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等系統性資訊。

目錄

簡介

概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:各適應症

開發中產品的概要

  • 後期階段的產品
  • 初期階段的產品
  • 開發階段不明的產品

開發中的產品:各企業

開發中的產品:各大學/研究機關

治療藥的評估

  • 單劑/聯合治療別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

開發治療藥的企業

  • Aduro BioTech, Inc.
  • Agenus, Inc.
  • Alligator Bioscience AB
  • AlphaMab Co., Ltd
  • CytomX Therapeutics, Inc.
  • Hanmi Pharmaceuticals, Co. Ltd.
  • JHL Biotech, Inc.
  • Lytix Biopharma AS
  • Novartis AG
  • OncoImmune, Inc.
  • Pfizer Inc.
  • Premier Biomedical Inc.
  • PsiOxus Therapeutics Limited
  • Sutro Biopharma, Inc.

藥物簡介

暫停的計劃

最新消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC1959TDB

Summary:

According to the recently published report 'Cytotoxic T Lymphocyte Protein 4 - Pipeline Review, H2 2019'; Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) pipeline Target constitutes close to 64 molecules. Out of which approximately 63 molecules are developed by companies and remaining by the universities/institutes.

Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) - CTLA4 also known as CD152 is a protein receptor found on the surface of T cells. It functions as an immune checkpoint and down regulates the immune system. The affinity of CTLA4 for its natural B7 family ligands, CD80 and CD86, is considerably stronger than the affinity of their cognate stimulatory co-receptor CD28. Inhibition of receptor acts as a major negative regulator of T-cell responses.

The report 'Cytotoxic T Lymphocyte Protein 4 - Pipeline Review, H2 2019' outlays comprehensive information on the Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 2, 8, 17, 1, 25 and 9 respectively. Similarly, the universities portfolio in Discovery stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology, Immunology and Infectious Disease which include indications Solid Tumor, Melanoma, Metastatic Melanoma, Non-Small Cell Lung Cancer, Breast Cancer, Colon Cancer, Gastric Cancer, Renal Cell Carcinoma, Small-Cell Lung Cancer, Colorectal Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Adenocarcinoma Of The Gastroesophageal Junction, Cervical Cancer, Metastatic Breast Cancer, Nasopharyngeal Cancer, Squamous Non-Small Cell Lung Cancer, Bladder Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Hepatocellular Carcinoma, Metastatic Colorectal Cancer, Metastatic Transitional (Urothelial) Tract Cancer, Ovarian Cancer, Peritoneal Cancer, Prostate Cancer, Transitional Cell Cancer (Urothelial Cell Cancer), Anal Cancer, Bile Duct Cancer (Cholangiocarcinoma), Gastroesophageal (GE) Junction Carcinomas, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Metastatic Renal Cell Carcinoma, Muscle Invasive Bladder Cancer (MIBC), Non-Hodgkin Lymphoma, Recurrent Head And Neck Cancer Squamous Cell Carcinoma, Soft Tissue Sarcoma, Anaplastic Thyroid Cancer, Endometrial Cancer, Esophageal Cancer, Esophageal Squamous Cell Carcinoma (ESCC), Germ Cell Tumors, Lung Cancer, Lymphoma, Malignant Pleural Mesothelioma, Medullary Thyroid Cancer, Merkel Cell Carcinoma, Metastatic Hepatocellular Carcinoma (HCC), Metastatic Pancreatic Cancer, Multiple Myeloma (Kahler Disease), Myelodysplastic Syndrome, Neuroblastoma, Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET), Osteosarcoma, Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Salivary Gland Cancer, Sarcomas, Triple-Negative Breast Cancer (TNBC), Vaginal Cancer, Vulvar Cancer, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Adenocarcinoma, Adenoid Cystic Carcinoma (ACC), Adrenal Gland Cancer, Adrenocortical Carcinoma (Adrenal Cortex Cancer), Advanced Malignancy, Basal Cell Carcinoma (Basal Cell Epithelioma), Bone Sarcoma, Chronic Lymphocytic Leukemia (CLL), Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Dedifferentiated Liposarcoma, Diffuse Large B-Cell Lymphoma, Dysgerminoma, Ependymoma, Epstein-Barr Virus (HHV-4) Infections, Ewing Sarcoma, Follicular Thyroid Cancer, Gallbladder Cancer, Germinomatous (Seminomatous) Germ Cell Tumors, Glioblastoma Multiforme (GBM), Gliosarcoma, Graft Versus Host Disease (GVHD), Head And Neck Cancer, Head And Neck Carcinoma, Hematological Tumor, High-Grade Glioma, Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Kaposi Sarcoma, Leukemia, Liver Cancer, Malignant Fibrous Histiocytoma, Malignant Mesothelioma, Medulloblastoma, Meningioma, Metastatic Biliary Tract Cancer, Metastatic Cancer, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Metastatic Liver Cancer, Metastatic Lung Cancer, Metastatic Ovarian Cancer, Metastatic Prostate Cancer, Metastatic Uveal Melanoma, Non-Small Cell Lung Carcinoma, Nongerminomatous (Nonseminomatous) Germ Cell Tumors, Oral Cavity (Mouth) Cancer, Oropharyngeal Cancer, Papillary Renal Cell Carcinoma, Papillary Thyroid Cancer, Pediatric Diffuse Intrinsic Pontine Glioma, Penile Cancer, Primitive Neuroectodermal Tumor (PNET), Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Rhabdomyosarcoma, Squamous Cell Carcinoma, Transitional Cell Carcinoma (Urothelial Cell Carcinoma), Ureter Cancer, Urethral Cancer, Urinary Tract Cancer.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4)
  • The report reviews Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) targeted therapeutics

Reasons to buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Introduction
  • Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) - Overview
  • Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) - Therapeutics Development
  • Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) - Therapeutics Assessment
  • Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) - Companies Involved in Therapeutics Development
  • Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) - Drug Profiles
  • Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) - Dormant Products
  • Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) - Discontinued Products
  • Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Therapy Areas, H2 2019
  • Number of Products under Development by Indications, H2 2019
  • Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
  • Number of Products under Development by Indications, H2 2019 (Contd..2), H2 2019
  • Number of Products under Development by Indications, H2 2019 (Contd..3), H2 2019
  • Number of Products under Development by Indications, H2 2019 (Contd..4), H2 2019
  • Number of Products under Development by Indications, H2 2019 (Contd..5), H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Number of Products under Development by Companies, H2 2019 (Contd..1)
  • Number of Products under Development by Companies, H2 2019 (Contd..2)
  • Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019 (Contd..1), H2 2019
  • Products under Development by Companies, H2 2019 (Contd..2), H2 2019
  • Products under Development by Companies, H2 2019 (Contd..3), H2 2019
  • Products under Development by Companies, H2 2019 (Contd..4), H2 2019
  • Products under Development by Companies, H2 2019 (Contd..5), H2 2019
  • Products under Development by Companies, H2 2019 (Contd..6), H2 2019
  • Products under Development by Companies, H2 2019 (Contd..7), H2 2019
  • Products under Development by Companies, H2 2019 (Contd..8), H2 2019
  • Products under Development by Companies, H2 2019 (Contd..9), H2 2019
  • Products under Development by Companies, H2 2019 (Contd..10), H2 2019
  • Products under Development by Companies, H2 2019 (Contd..11), H2 2019
  • Products under Development by Companies, H2 2019 (Contd..12), H2 2019
  • Products under Development by Companies, H2 2019 (Contd..13), H2 2019
  • Products under Development by Companies, H2 2019 (Contd..14), H2 2019
  • Products under Development by Companies, H2 2019 (Contd..15), H2 2019
  • Products under Development by Companies, H2 2019 (Contd..16), H2 2019
  • Products under Development by Companies, H2 2019 (Contd..17), H2 2019
  • Products under Development by Companies, H2 2019 (Contd..18), H2 2019
  • Products under Development by Companies, H2 2019 (Contd..19), H2 2019
  • Products under Development by Companies, H2 2019 (Contd..20), H2 2019
  • Products under Development by Companies, H2 2019 (Contd..21), H2 2019
  • Products under Development by Companies, H2 2019 (Contd..22), H2 2019
  • Number of Products under Investigation by Universities/Institutes, H2 2019
  • Products under Investigation by Universities/Institutes, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019
  • Number of Products by Stage and Molecule Type, H2 2019
  • Pipeline by Abeome Corp, H2 2019
  • Pipeline by Aduro BioTech Inc, H2 2019
  • Pipeline by Agenus Inc, H2 2019
  • Pipeline by Akeso Biopharma Inc, H2 2019
  • Pipeline by Alligator Bioscience AB, H2 2019
  • Pipeline by AlphaMab Co Ltd, H2 2019
  • Pipeline by Alpine Immune Sciences Inc, H2 2019
  • Pipeline by Anaeropharma Science Inc, H2 2019
  • Pipeline by Apollomics Inc, H2 2019
  • Pipeline by AstraZeneca Plc, H2 2019
  • Pipeline by BeyondSpring Inc, H2 2019
  • Pipeline by Biocad, H2 2019
  • Pipeline by Biosortia Pharmaceuticals, H2 2019
  • Pipeline by BJ Bioscience Inc, H2 2019
  • Pipeline by Bristol-Myers Squibb Co, H2 2019
  • Pipeline by Cancure Ltd, H2 2019
  • Pipeline by Cellective BioTherapy Inc, H2 2019
  • Pipeline by Cold Genesys Inc, H2 2019
  • Pipeline by Cstone Pharmaceuticals Co Ltd, H2 2019
  • Pipeline by DotBio Pte Ltd, H2 2019
  • Pipeline by Five Prime Therapeutics Inc, H2 2019
  • Pipeline by GigaGen Inc, H2 2019
  • Pipeline by Harbour BioMed, H2 2019
  • Pipeline by Hengenix Biotech Inc, H2 2019
  • Pipeline by Hualan Biological Engineering Inc, H2 2019
  • Pipeline by Immunocore Ltd, H2 2019
  • Pipeline by Immunwork Inc, H2 2019
  • Pipeline by Immutics Inc, H2 2019
  • Pipeline by Innovent Biologics Inc, H2 2019
  • Pipeline by Inovio Pharmaceuticals Inc, H2 2019
  • Pipeline by JHL Biotech Inc, H2 2019
  • Pipeline by Jiangsu Alphamab Biopharmaceuticals Co Ltd, H2 2019
  • Pipeline by MacroGenics Inc, H2 2019
  • Pipeline by Merck & Co Inc, H2 2019
  • Pipeline by Momenta Pharmaceuticals Inc, H2 2019
  • Pipeline by Nanjing Jinsirui Biotechnology Co Ltd, H2 2019
  • Pipeline by OncoImmune Inc, H2 2019
  • Pipeline by Premier Biomedical Inc, H2 2019
  • Pipeline by Regeneron Pharmaceuticals Inc, H2 2019
  • Pipeline by Replimune Ltd, H2 2019
  • Pipeline by Serometrix LLC, H2 2019
  • Pipeline by Shanghai Henlius Biotech Inc, H2 2019
  • Pipeline by Shanghai Junshi Bioscience Co Ltd, H2 2019
  • Pipeline by Shanghai Mab Venture Biopharm Co Ltd, H2 2019
  • Pipeline by Sorrento Therapeutics Inc, H2 2019
  • Pipeline by Sound Biologics, H2 2019
  • Pipeline by Stcube Inc, H2 2019
  • Pipeline by Tikcro Technologies Ltd, H2 2019
  • Pipeline by Xencor Inc, H2 2019
  • Dormant Products, H2 2019
  • Dormant Products, H2 2019 (Contd..1), H2 2019
  • Dormant Products, H2 2019 (Contd..2), H2 2019
  • Discontinued Products, H2 2019
  • Discontinued Products, H2 2019 (Contd..1), H2 2019

List of Figures

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Therapy Areas, H2 2019
  • Number of Products under Development by Top 10 Indications, H2 2019
  • Number of Products by Mechanism of Actions, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Routes of Administration, H2 2019
  • Number of Products by Stage and Routes of Administration, H2 2019
  • Number of Products by Top 10 Molecule Types, H2 2019
  • Number of Products by Stage and Top 10 Molecule Types, H2 2019
Back to Top